SOURCE: IDenta Corp.

January 09, 2008 10:00 ET

International Drug & Explosives Detection Company IDenta Receives Patent for New Heroin Drug Detector -- Additional Product Patents Being Processed

HEATHROW, FL--(Marketwire - January 9, 2008) - IDenta Corp. (PINKSHEETS: IDTA) announced today that it has recently been awarded a new patent from the European Patent Office. The patent is for the development of IDenta's new Heroin Drug Detection Kit, which is currently being produced in Israel and marketed in many countries throughout the world. The IDenta Heroin kit is a two step test (step 1 - detection, step 2 - confirmation) and it is the only reliable kit on the market, with no false positives.

The IDenta Heroin Drug Detection kit patent number is 0983514 and is designated for "A Process and Test Kit for Heroin Detection."

IDenta has applied recently to receive patents for the new GHB Drug Detector and for the TATP explosive detector. Further company updates will be published as they become available.

ABOUT IDENTA

IDenta Corp. has rapidly become recognized as a world-wide leader in the development of a variety of substance detection kits including proprietary on-site drug detection kits and explosive detection kits. IDenta develops, manufactures and distributes products for the both professional and civil markets which consistently pass the highest qualifications and testing procedures of law enforcement and security agencies around the world. Information concerning IDenta's entire product line may be found at www.identa.biz.

Certain of the statements contained herein may be, within the meaning of the federal securities laws, "forward-looking statements" that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management's expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.

Contact Information

  • Contact:

    For Investor Relations, lobbying interests or information
    concerning IDenta's products internationally contact:

    Yaacov Shoham
    IDenta Corp.
    CEO
    Tel: +972-52-6554487
    +972-8-9716874
    Fax: +972-8-9716875
    fpi@drugsdetector.com
    www.identa.biz
    www.drugsdetector.com

    For Investor Relations in the United States contact:
    Randy Jacobs
    US Corporate Spokesman
    IDentaNews@sitcomllc.com
    1-800-316-9437

    For more information about IDenta's product line in the United States
    please contact:
    Mr. Eyal Golan
    COO
    JANT PHARMACAL CORPORATION
    16255 Ventura Blvd. #505
    Encino, CA 91436
    Toll Free: 800-676-5565
    www.accutest.net